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The cornea is an immune privileged tissue. Since arginase has been found to modulate
T-cell function by depleting arginine, we investigated the expression of arginase in the
cornea and its possible role in immune privilege using a murine transplant model. We
found that both the endothelium and epithelium of murine corneas express functional
arginase I, capable of down-regulating T-cell proliferation in an in vitro culture system.
The administration of the specific arginase inhibitor N-hydroxy-nor-L-Arg to recipient
mice resulted in an accelerated rejection of allogeneic C57BL/6 (B6) corneal grafts. In
contrast, in vivo blockade of arginase activity had no effect in altering the course of
rejection of primary skin grafts that express little, if any, arginase. In addition, the inhi-
bition of arginase did not alter systemic T-cell proliferation. These data show that arginase
is functional in the cornea and contributes to the immune privilege of the eye, and that
modulation of arginase contributes to graft survival.
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Introduction
The cornea is immune privileged, as evidenced by the high
success rate of corneal grafts (typically 90% at one year [1]) in
the absence of systemic immunosuppression or HLA matching.
There are several factors contributing to immune privilege [2],
including (i) the absence of blood and lymphatic vessels in the
graft bed [3], (ii) the expression of Fas ligand in corneal
epithelial and endothelial cells [4], (iii) low expression levels of
major histocompatibility complex class I and II molecules in
corneal cells [5, 6], (iv) the atypical nature of the antigen-
presenting cells within the cornea [7], (v) anterior chamber-
associated immune deviation (ACAID) where systemic delayed-
type hypersensitivity is down-regulated following exposure
of the anterior chamber to alloantigens [8], and (vi) the presence
of immunomodulatory cytokines such as transforming growth
factor-b in aqueous humour in the anterior chamber of the
eye [9].
L-arginine (L-Arg) is a semi-essential amino acid for adult
mammals. Thus, while the body can synthesize some L-arginine,
in some conditions, such as trauma and pregnancy, in which
demand increases, it is necessary to supplement with dietary
L-Arg [10]. L-Arg is metabolized by two independent enzymatic
pathways, involving the enzymes arginase and nitric oxide
synthase (NOS) [11]. Arginase hydrolyzes L-Arg into urea and
L-ornithine, the latter being a precursor of polyamines (putres-
cine, spermidine and spermine) that are required for cell prolif-
eration. NOS converts L-Arg into citruline and nitric oxide (NO),
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which are important in vascular homeostasis [11] and macro-
phage cytotoxicity [12].
The two identified arginase isoforms, arginase I and arginase
II, differ in tissue distribution, subcellular localization and regu-
lation [13]. Arginase-mediated L-Arg depletion has been shown to
down-regulate T-cell functions in various systems. Thus, tumour-
associated myeloid cells express arginase I, and inhibition of the
enzyme can slow tumour growth, suggesting that arginase I in the
tumour microenvironment may be important for tumour escape
[14, 15]. T-cell functions are also suppressed by human granu-
locyte arginase [16]. In human pregnancy, arginase activity is
enhanced in both the peripheral blood and term placenta,
resulting in T-cell hyporesponsiveness [17].
In this study, we investigated the hypothesis that arginase is
involved in the maintenance of immune privilege in the eye. Our
data show that both murine corneal endothelium and epithelium
express functional arginase capable of down-regulating T-cell
proliferation in an in vitro culture system. In a murine model of
corneal allograft transplantation, inhibition of arginase in vivo
accelerated corneal allograft rejection, but had no effect on the
survival of transplanted donor skin that expresses little arginase.
Therefore, arginase plays an important role in the maintenance
of immune privilege in the eye by contributing to allograft
acceptance.
Results
Functional arginase is expressed in murine corneas
We examined the expression of arginase in whole murine
corneas. BALB/c corneas were homogenized and tissue extracts
were assessed for arginase expression at the mRNA and protein
levels by real-time PCR and Western blotting, respectively. The
expression of arginase was compared with that in liver, heart,
lung, kidney, spleen and intestine. Arginase I mRNA was
detectable in resting murine corneas (Fig. 1A). The level of
arginase I in resting corneas was nearly a tenth of that in liver,
which has the highest expression of arginase I. No expression of
arginase I mRNA was found in heart, lung, spleen and intestine.
The mRNA expression of arginase I was consistent with arginase I
protein expression shown by Western blot using anti-arginase I
antibody (Fig. 1B). In contrast, we were unable to detect
arginase II mRNA or protein expression in the cornea. Strongest
arginase II expression was seen in the intestine, followed by
kidney and liver (Fig. 1A and B). To test whether the arginase
present in the corneas was functional, we measured arginase
enzymatic activity in murine corneas and compared it with other
tissues. Arginase activity in unmodified resting murine corneas
was easily detectable. It was lower than that in liver, intestine and
kidney, but significantly higher than that in heart, lung and
spleen (Fig. 1C).
To address, in part, the question of whether arginase function
in vivo in the cornea might be altered during inflammation,
corneas were cultured in the presence of murine cytokines IL-4,
TNF-a and IFN-g. These are reported to induce arginase expression
in murine macrophages [18]. A marginal increase in the mRNA
expression of arginase I was seen in corneas stimulated with either
IL-4 or TNF-a, but no change was seen with IFN-g (Fig. 1D). No
arginase II expression was seen under any conditions.
Immunohistochemistry was used to localize expression of
arginase I and II in the cornea. Staining for arginase I but not
arginase II was found in the endothelium and epithelium
of the cornea (Fig. 1E). This was confirmed using RT-PCR
analysis, which showed that arginase I mRNA was present
in both the epithelium and endothelium of the murine cornea
(Fig. 1F).
Arginase in corneas has inhibitory effect on T-cell
proliferation
To examine the functional effect of corneal arginase, corneas
were homogenized and the tissue extracts were added to purified
CD41 T cells stimulated with anti-CD3 and anti-CD28 beads in
the presence or absence of competitive arginase inhibitors,
N-hydroxy-nor-L-arginine (nor-NOHA), (S)-(2-Boronoethyl)-L-
cysteine (BEC) or 0.1mM L-arginine. 3H thymidine was added
to T cells on day 4 and cells were harvested 16 h later. As shown
in Fig. 2, addition of corneal extracts inhibited the proliferation
of the T cells; this inhibition could be partially restored by
addition of either nor-NOHA, BEC or L-arginine (po0.05). These
data indicate that arginase in corneal extracts is, in part,
responsible for the observed inhibition of T-cell proliferation.
A similar result was also seen with liver extracts. Addition of
nor-NOHA or BEC had no effect on T-cell proliferation in the
absence of tissue extracts. In contrast, addition of nor-NOHA had
no effect on the inhibition of T-cell proliferation caused by lysates
of heart tissue.
Inhibition of arginase shortens corneal allograft
survival
Having found that the cornea expresses arginase I, which inhibits
in vitro T-cell proliferation, we then tested the possibility that
functional arginase expressed by the cornea might prevent or
delay corneal allograft rejection. As arginase knock-out mice do
not live beyond 12 days [19], we used a competitive
arginase inhibitor, nor-NOHA, in vivo. C57BL/6 (B6) strain
mouse corneas were grafted as orthotopic transplants to BALB/c
recipients randomized to receive daily intraperitoneal injections
of either nor-NOHA at 100mg/kg/day or control PBS from day 1
to day 21 post-transplantation. The rejection of B6 corneas in the
nor-NOHA treatment group was accelerated compared with
that of control group (p50.014). Graft rejection onset ranged
from day 11 to day 35, with 22% long-term survival.
In contrast, control graft rejection ranged between days 25 and
33 with 61% long-term survival (Fig. 3A). Syngeneic grafts
survived indefinitely.
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Inhibition of arginase has no effect on skin allograft
survival
Inhibition of arginase might shorten corneal allograft survival
either by local action on arginase activity within the transplant
graft or by systemic modulation of the allograft response [20]. To
determine which is the case, we performed B6 male to female
skin transplants. This donor–recipient combination was chosen
because it has similar rejection kinetics as the B6 to BALB/c
corneal transplantation model. RT-PCR analysis revealed that
neither donor tail skin nor shank skin (site of the graft bed)
express arginase I and minimal arginase II (Fig. 3B). Recipients
were randomized to receive either nor-NOHA at 100mg/kg/day
or control PBS from day 1 to day 21 post-transplantation. Figure
3C shows that the rejection of skin grafts in the nor-NOHA
treatment group is similar to that of the control group (p5 0.6).
Inhibition of arginase has no effect on systemic T-cell
proliferation
To further investigate the effect of arginase inhibition on systemic
T-cell response, we tested the ability of T cells to proliferate after
administration of the arginase inhibitor, nor-NOHA. Splenocytes
from Thy1.11 Rag2/ Marilyn mice were stained with CFSE and
adoptively transferred into B6 females (Thy1.21) by i.v. injection.
On the same day (day 0), all recipients were immunized with
male splenocytes. From day 1 to day 7, the animals received
either nor-NOHA at 100mg/kg/day or PBS. At day 5 and day 10,
three mice from each group were killed and splenocytes were
stained for Thy1.1. Figure 4 shows a similar degree of
proliferation of male-specific T cells in animals receiving nor-
NOHA or PBS, suggesting that inhibition of arginase has little
systemic effect on T-cell proliferation.
Figure 1. Expression of arginase I by murine cornea. (A) Real-time PCR analysis of arginase I (top) and arginase II (bottom) in murine cornea and
other tissues. Total RNA was extracted from cornea and other tissues, and arginase mRNA was quantified by real-time PCR. Arginase mRNA levels
were normalized to HPRT. (B) Western blotting for arginase protein. Tissues were homogenized and the supernatants were run on SDS-PAGE and
probed for both arginase I and II. GAPDH was used as a loading control. (C) Arginase activity was measured in tissue extracts. Tissues were
homogenized and the supernatants were taken to measure arginase activity by conversion of L-Arg into urea. Urea concentrations were assessed
using a colorimetric assay, using the conversion of a-isonitrosopropiophenone; 1 unit of enzyme arginase activity catalyses the formation of
1 mmol urea/min. Data are represented as the mean1SD. (D) Effect of cytokine stimulation on arginase I mRNA expression in cornea. Arginase I
mRNA levels were normalized to HPRT. (E) Immunohistochemical staining of the cornea with antibodies against Arginase I or II and isotype
controls show expression in both the endothelium and epithelium. Magnification: 20 . (F) Epithelium and endothelium of cornea were separated
surgically. Total RNA was extracted and arginase I mRNA expression was analysed by RT-PCR. Data are representative of three independent
experiments, and in each group (A, C and D) triplicates were performed.
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The inhibition of arginase does not alter NO-
dependent apoptosis of corneal endothelial cells
Non-dividing corneal endothelial cells are critical for the
maintenance of corneal transparency and thus are essential to
graft survival [21]. We have shown that the pro-inflammatory
cytokines, IL-1, TNF-a and IFN-g, induce apoptosis of corneal
endothelium through an NO-dependent pathway [22]. Since
arginase and NOS share the same substrate [11], it is possible
that the arginase inhibition would result in an increase in NO
production through the NOS pathway, thus accelerating graft
destruction. To investigate this, murine corneal endothelial cells
(MCECs) were exposed to different concentrations of cytokines in
the presence of either the arginase inhibitor nor-NOHA, or the
NOS inhibitor L-NAME (5 mM). NO level in the supernatant of
cultured cells was subsequently measured. As shown in Fig. 5A,
the cytokines increased NO production by MCECs, as previously
shown. L-NAME significantly reduced the production of NO;
however, nor-NOHA did not alter the production of NO.
Therefore, L-Arg was probably not limiting for NO production
by NOS in this setting. As expected, considerable cell apoptosis
was observed in MCECs stimulated with IL-1, TNF-a and IFN-g.
The NOS inhibitor L-NAME, but not the arginase inhibitor nor-
NOHA, inhibited cytokine-induced apoptosis (Fig. 5B).
Discussion
Corneal transplantation is highly successful without tissue
matching and systemic immunosuppressive therapy due to the
immune privilege of the eye, with around 90% of grafts surviving
1 year, though this drops to 75% at 5 years [23]. Lack of
lymphatic drainage [3], the atypical nature of the APCs within
the cornea [7], limited MHC expression [5, 6], FasL expression
[4], the tendency to induce anterior chamber-associated immune
deviation [8] and immunosuppressive cytokines [24, 25] have all
been associated with immune privilege. Here, we reveal for the
first time that the murine cornea expresses functional arginase I
that plays an important role in the maintenance of immune
privilege of corneal allografts.
Arginase is expressed in various tissues and organs. Consistent
with previous reports [26], we found that the murine liver
expresses high levels of arginase I and low levels of arginase II.
The kidney, intestine and spleen express only arginase II. Argi-
nase, by virtue of its ability to deplete arginine, can be an effector
mechanism of the immune system. Arginase expression by
tumour and human term placenta have been found to suppress
T-cell responses [14, 17]. This is due to the L-Arg depletion by
arginase. It has been demonstrated that L-Arg availability can
modulate T-cell function. Arginase-mediated L-Arg depletion
induces down-regulation of CD3z, the main signalling chain of
TCR [27]. Therefore, arginase has been suggested to play a role
in local immune suppression.
This is the first report of functional arginase I expression in the
cornea and several lines of evidence suggest that arginase may be
an additional factor in the comparative immune privilege of this
tissue. We found that both corneal endothelium and epithelium
expressed arginase I. We also found that tissue extracts from
murine corneas inhibited T-cell proliferation, which could be
partly reversed by either nor-NOHA or BEC or by supplementa-
tion of the medium with L-arginine, thus demonstrating the
presence of functional arginase in the cornea. When the compe-
titive arginase inhibitor, nor-NOHA, was systemically adminis-
tered, the rejection of corneal allografts was accelerated.
Consistent with our finding, it has been reported that arginase I
mRNA was present in murine cornea but arginase II mRNA was
not detected. Expression of both arginase I and arginase II were
elevated in the cornea at late stages of ocular herpes simplex
virus type-1 infection [28].
Arginase can operate either locally or systemically to suppress
the immune response [20]. Therefore, the shortening of graft
survival may be due to systemic, rather than local, effects.
Consistent with another report [29], there is no arginase in the
murine skin, although expression has been seen in human skin
[30]. However, in skin allografts, which do not express arginase I,
there was no effect of nor-NOHA treatment. Furthermore, inhi-
bition of arginase had no effect on the T-cell proliferation
following systemic immunization. Therefore, it is likely that
arginase is operating locally to down-regulate the rejection in the
tissue, rather than affecting the priming or initial activation of the
alloreactive T cells.
This is the first report of arginase function in transplantation
immunology. While we have shown that arginase has a role in
preventing corneal graft rejection, though not skin graft rejection,
it is interesting to speculate that it may also have a role in other
organ allografts. This is especially the case for the liver, which has
high levels of arginase and allografts of which can undergo
spontaneous acceptance in animal models [31, 32].
Figure 2. Effect of corneal arginase on T-cell proliferation. Tissues
from cornea, heart and liver were homogenized and the supernatants
(10 mL) were added to purified CD41 T cells stimulated with anti-CD3
and -CD28 beads in the presence or absence of the arginase inhibitors,
nor-NOHA, BEC, or 0.1 mM L-arginine in 96-well plates. T-cell prolifera-
tion was determined by 3H thymidine incorporation after 3 days
(po0.05, Student’s t-test). Data are representative of three independent
experiments, and in each group triplicates were performed. Error bars
indicate SD.
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As arginase and NOS share L-arginine as their primary
substrate [11], it is possible that inhibition of arginase might
increase the production of NO. Inflammatory cytokines induce
apoptosis of corneal endothelial cells in an NO-dependent
manner [22], and it is conceivable that arginase inhibition might
potentiate this effect. However, there was no difference in either
NO levels generated by MCEC cells, or in their apoptosis,
following stimulation by a cocktail of cytokines in the presence or
absence of nor-NOHA. There are conflicting reports regarding the
role of arginase in regulating NO synthesis. Some studies suggest
that arginase activity regulates the availability of L-Arg as a
substrate for NOS in endothelial cells [33, 34], while others show
arginase activity has no effect on NO production in macrophages
[35]. These differences may reflect whether arginine is limiting in
particular systems.
In higher organisms, the control of amino acid metabolism is a
strategy for limiting the unwanted proliferation of cells, including
T cells [36]. L-Arg is not the only amino acid with effects on the
immune system. Indoleamine 2,3-dioxygenase (IDO) is another
enzyme metabolizing the essential amino acid L-tryptophan that
can modulate the function of the immune system [37]. IDO has
been involved in the maintenance of immune privilege in the
placenta [38]. We previously found expression in murine cornea
of functional IDO; overexpression of IDO in the donor corneas
prolonged allograft survival. However, it is noteworthy that
inhibition of IDO had no effect on corneal allograft survival [39].
This report of arginase activity is another example of the ability of
the eye to inhibit the proliferation of infiltrating T cells by
enzyme-mediated amino acid starvation, contributing to the
immune privilege of corneal allografts.
Materials and methods
Cell culture
SV-40-immortalized BALB/c corneal endothelial cells (MCECs)
[40], a gift of Dr J. Y. Niederkorn, Dallas, TX, were maintained in
Eagle’s MEM supplemented with 1% (vol) penicillin and
streptomycin and non-essential amino acids (Gibco-BRL, Paisley,
UK) and 10% heat-inactivated FCS (Gibco-BRL) [22].
RNA extraction and reverse transcription
Corneal or other tissues were ground using the beads and reagent
supplied with the Fast RNA Pro Green Kit (QBiogene, Carlsbad,
CA, USA). Corneal tissue was separated by dissection surgically
into epithelium, and endothelium. RNA extraction and quantifi-
cation was performed as previously described [21].
Quantitative PCR
The PCR protocol was performed using an Applied Biosystems
machine and the Power SYBR Green mastermix (Applied Biosystems,
UK) with an initial denaturation step at 951C for 5min followed by
40 cycles of amplification (denaturation at 951C for 5 s, annealing at
601C for 10 s, elongation at 721C for 13 s), and quantification at 811C
[39]. Quantification of arginase I mRNA was carried out using
the primers 50-ACCTGGC CTTTGTTGATGTC-30 (forward) and
50-ACTGCCAGACTGTGGTCTCC-30 (reverse) spanning 160bp of
Figure 3. Inhibition of arginase shortens corneal allograft survival but
not skin graft survival. (A) BALB/c (H2d) mice received unilateral C57BL/6
(H2b) donor corneal allografts and intraperitoneal injections of either nor-
NOHA at 100mg/kg/day (n514) or PBS (n513) from day 1 to day 21.
Pooled results from two independent experiments are shown. Allograft
survival was assessed by determining the opacity of the cornea using an
objective scale, as described in [44]. (B) RT-PCR analysis of arginase
expression in donor tail skin and recipient shank skin. cDNA was
prepared from tissues, and PCR was carried out using HPRT, arginase I
and II primers and the product was run on a 1.5% agarose gel. Data are
representative of three independent experiments. (C) B6 female mice
received B6 male donor skin allografts and intraperitoneal injections of
either nor-NOHA at 100 mg/kg/day (n58) or PBS (n58) from day 1 to
day 21.
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the gene. Quantification of arginase II mRNA was carried out using
the primers 50-CTGCCATTCGAGAAGCTGG-30 (forward) and
50-GGGATCATCTTGTGG ACATTAG-30 (reverse) (spanning 104bp)
[41]. Quantification of hypoxanthine phosphoribosyl transferase
(HPRT) mRNA was carried out using the primers 50-ATGAT
CCAGTCAACGGGGGAC-30 (forward) and 50-CCAGCAAGCTTG
CAACCTTAACCA-30 (reverse) (spanning 177bp).
Immunoperoxidase staining
Tissue sections (8mm, embedded in OCT) were allowed to
dry at room temperature for 2 h, treated with 3% H2O2 in
methanol. Blocked with normal goat serum (1:25 with PBS)
and then treated with 0.1% Triton X-100 in PBS. After
three washes in PBS, sections were incubated with either
rabbit anti-mouse arginase I or rabbit anti-mouse arginase II
(Santa Cruz, USA) diluted 1:100 for 18h at 41C. After
washing in PBS, sections were incubated with horseradish
peroxidase- (HRP) conjugated goat anti-rabbit IgG (Dako,
Denmark) diluted 1:50 for 1 h at room temperature. After
washes with PBS, the chromogen 3,30-diaminobenzidine tetra-
hydrochloride (DAB enhanced liquid substrate system; Sigma,
D3939) was applied at 100–200mL for 2–5min. The sections
were washed in tap water before haematoxylin counterstaining
for 30 s.
Western blotting
Corneal tissue was ground using the beads as described above.
After centrifugation, the supernatant was separated on 10% SDS-
PAGE under reducing conditions and transferred to nitrocellulose
membrane using electrophoresis. Membranes were probed using
either rabbit anti-mouse arginase I antibody or rabbit anti-mouse
arginase II antibody, followed by HRP goat anti-rabbit IgG
antibody. Blots were developed using ECL plus system (Amer-
sham Pharmacia Biotech).
Arginase activity
The enzymatic activity of arginase was measured as previously
described [42].
Figure 4. Inhibition of arginase has no effect on systemic T-cell proliferation. Splenocytes from Thy1.11 Rag2/ Marilyn mice were stained with
CFSE and adoptively transferred into B6 females (Thy1.21) by i.v. injection. On the same day (day 0), all recipients were immunized with male
splenocytes. From day 1 to day 7, B6 female mice received intraperitoneal injections of either nor-NOHA at 100 mg/kg/day or PBS. At days 5 and 10,
three mice from each group were sacrificed and splenocytes were analysed by two-colour flow cytometry. Lymphocytes were gated on forward and
side scatter and shown for expression of Thy1.1 (y axis) and CFSE (x axis). Three animals were used per time point for each group. Error bars
indicate SD. Student’s t-test was used to generate the p-values described.
Figure 5. Nor-NOHA does not increase NO production by MCECs
exposed to a cocktail of cytokines. MCECs were treated with different
concentrations of the proinflammatory cytokines IL-1, TNF-a and IFN-g
(10–100 ng/mL) and cultured in the presence or absence of nor-NOHA
(0.6 mM) or L-NAME (5 mM), for 48 h. (A) NO level in the supernatant of
cultured cells using Griess reagent following conversion of nitrate into
nitrite. (B) Analysis of cell apoptosis by Annexin-V staining. Data are
representative of three independent experiments. Student’s t-test was
used to generate the p-values described.
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Cytokine treatment
Recombinant murine pro-inflammatory cytokines TNF-a, IL-1a
and IFN-g (PeproTech EC, London, UK) were added directly to
cell cultures at final concentrations of between 10 and 100ng/mL
and cultured for 48 h.
In vitro T-cell proliferation assays
Spleen cells from C57BL/6 mice were treated with a mixture of
anti-CD45R/B220, anti-CD8 and anti-MHC class II supernatants
(RA3-3A1, M5/114, 53.6.7 and 2.4G2) for 30min. After antibody
treatment, the cells were washed and incubated with goat anti-
mouse IgG and goat anti-rat IgG-coated beads (Dynal, Brombor-
ough, UK) for 30min, followed by removal of bound cells with a
magnet [39]. Responder CD41 T cells (1 105 cells/well) were
stimulated with beads coated with anti-mouse CD3 and CD28.
Tissues were ground using the beads. After centrifugation, 10 mL
of supernatant from the homogenized tissues was mixed with
MnCl2 and added to the T cells in the presence or absence of
10 mM competitive arginase inhibitors L-2-Amino-(4-(20-hydro-
xyguanidino)butyric Acid (nor-NOHA) or BEC, or 0.1mM
L-arginine in 96-well plates. Proliferation was measured by a
16-h pulse with 3H thymidine (10 mL, 5 mCi/mL, Amersham
Pharmacia Biotech).
Measurement of apoptosis by Annexin V staining
This has been done according to manufacture’s protocol (BD
PharmingenTM, 556421).
Nitric oxide colorimetric assay
The NO level was measured using the Nitric Oxide Colorimetric
Assay Kit (BioVision, K262-200) according to the manufacturer’s
protocol.
In vivo T-cell proliferation assays
Spleen cells from Thy1.11 Rag2/ Marilyn mice (TCR trans-
genic with specificity for HY/Dby peptide [43], provided by Dr.
O. Lantz, Paris, France) were stained with CFSE (4 mM) and
adoptively transferred into B6 females (Thy1.21) by i.v. injection
(2106 cells/mouse). On the same day (day 0), all recipients
were immunized with male splenocytes. From day 1 to day 7, B6
female mice received intraperitoneal injections of either nor-
NOHA at 100mg/kg/day or PBS. At day 5 and day 10, three mice
from each group were killed and splenocytes were stained for
Thy1.1 marker. Cells were gated on Thy1.1 (eBioscience) positive
population. Proliferation was measured by CFSE (Invitrogen)
dilution.
Corneal transplantation
Orthotopic corneal transplantation was performed using a modifi-
cation of a technique described previously [44, 45]. Briefly, donor
C57BL/6 (H2b), (B6) corneas were excised using a 2.0-mm trephine
(Duckworth & Kent, England). The right corneas of recipients were
excised with Vannas scissors (Duckworth & Kent). B6 corneas were
then applied to BALB/c corneal beds, secured with 8–9 continuous
11/0 nylon sutures. Sutures were removed on day 7, at which time
any grafts showing technical failures were excluded from the study
[44]. The specific arginase inhibitor N-hydroxy-nor-Arg (Bachem,
Germany) was injected intraperitoneally (i.p.) at 100mg/kg/day
for the treatment group (Control animals received the same volume
of PBS). All animals were obtained from Harlan Olac (Bicester, UK)
and treated in accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research and United Kingdom
Home Office Guidance.
Skin transplantation
Skin grafting was conducted as described by Billingham and
Medawar [46] using tail skin grafted onto the lateral thorax.
Plasters were removed after 8 days and grafts were examined
every 2 days until rejection (o10% of the original graft remains
viable).
Statistical analysis
Mean values with SD are shown where appropriate. Statistical
significance was determined using Student’s t-test. Differences in
graft survival were analysed using log rank test and actuarial
survival plotted according to the Kaplan–Meyer method. A value
of po0.05 was regarded as statistically significant.
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